HIGHLIGHTS
- who: Anastasia Lyon and collaborators from the Department of Pharmacology and Nutritional Sciences, College of Medicine, University of Kentucky, Lexington, KY, USA have published the research: ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization, in the Journal: Cancers 2023, x of 11/Oct/2022
- what: Using both loss-of-function and gain-of-function approaches the authors show that ABL1/2 and are critical nodes during NRAS-mutant melanoma intrinsic and acquired MEK inhibitor (MEKi) resistance. The authors demonstrate that DDR1 contributes to . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.